Greenlane Holdings closed the second quarter with a BERA treasury worth $16.4 million against a $70 million cost basis, a 76.6 percent decline that produced a $19.1 million noncash fair-value loss and helped push the company to a $24.8 million net loss for the period. The Nasdaq-listed firm, which pivoted from cannabis accessories to a single-token treasury strategy in October 2025, now holds 81.3 million BERA and equivalent tokens, up from 77.7 million at the end of March, even as the asset trades near $0.146, down 75.9 percent year to date.
The pivot that concentrated risk
The company raised $110.7 million in a private placement last autumn and designated BERA as its primary reserve asset, effectively betting the balance sheet on a layer-one blockchain that had yet to launch its mainnet. That concentration meant the quarterly mark-to-market captured the full force of a token that briefly topped $1.20 earlier this year before sliding steadily toward fifteen cents. The $53.8 million paper gap between cost and fair value is not a trading loss, Greenlane has not sold, but it does mean the treasury now covers roughly twenty-three cents per dollar of invested capital.
Yield does not offset the mark
Staking and yield revenue from the digital-asset segment came to $309,000 for the quarter, a figure that rounds to zero against the $19.1 million valuation hit. The company is earning a return on an asset that has lost three-quarters of its value since January, a dynamic that works until the treasury needs liquidity or the token faces a further re-rating. Greenlane’s filing does not disclose a hedging program or a diversification timeline.
The survival threshold
With the token down 75.9 percent year to date and the treasury sitting at less than a quarter of cost, the question shifts from strategy to solvency runway. Greenlane’s cash position and operating burn were not detailed in the Friday filing, but a $24.8 million quarterly net loss against a $16.4 million digital-asset book leaves little margin for error. The next quarterly report will show whether the company continues accumulating BERA at these levels or whether the board treats the concentration as a risk that requires correction.